TL;DR: On our production line, emulsification runs at 75–80°C
TL;DR: Preservation systems in finished cosmetics typically push pH into the 4.5–5.5 range
Key Technical Parameters #
Selecting the right probiotic or postbiotic raw material is where most microbiome briefs either move forward or stall out for weeks. Brand partners typically arrive with a concept and a claimed CFU count — but the specification parameters that actually determine formulation success are particle size distribution, acid tolerance, thermal stability ceiling, and lysate protein concentration. These four parameters vary dramatically across commercially available grades and directly affect everything from emulsion texture to shelf-life claims. At Mastracare, the first filter we apply when evaluating a new microbiome ingredient isn’t efficacy data — it’s whether the supplier can provide a complete technical data sheet against measurable, reproducible benchmarks.
The Specification Parameters That Drive Formulation Outcomes #
Brands usually ask about CFU count first. We understand why — it’s the most marketable number. But in our incoming inspection protocol (logged under what we call the MB-IQ criteria, our internal material intake qualification checklist), CFU is actually the last parameter we verify, not the first.
Thermal stability ceiling matters more. On our production line, emulsification runs at 75–80°C. Any live probiotic strain that can’t tolerate at least 85°C for 10 minutes in dry encapsulated form will lose viability before the batch reaches the filling station. We’ve run temperature excursion tests on seven commercial Lactobacillus grades over the past two years and found that three of them failed to maintain viable counts above 10⁸ CFU/g after a 15-minute hold at 80°C — despite supplier certificates claiming 10¹⁰ CFU/g at time of manufacture.
Acid tolerance is the second filter. Preservation systems in finished cosmetics typically push pH into the 4.5–5.5 range. Encapsulated strains that aren’t buffered against this environment can lose more than 2 log cycles in viability within 6 weeks at ambient temperature. That’s not a theoretical risk — it showed up consistently in our 2023 stability audit across five different brand briefs using unbuffered microencapsulated Lactobacillus acidophilus.
Particle size is where texture claims get made or broken. For serums targeting a water-thin viscosity, encapsulated probiotic particles above 50 µm create detectable grittiness in consumer use testing. For creams, you can push to 80–100 µm without perceptible texture change, but beyond that you’ll see phase separation during storage at 40°C. Our texture acceptance threshold is 50 µm for leave-on serums and 100 µm for wash-off or cream formats — anything above those limits gets flagged before we even run a pilot batch.
For postbiotic lysates and ferment filtrates, protein concentration (typically measured as mg/mL by BCA assay) is the primary specification driver. This is where supplier data and our own incoming QC diverge most often. We regularly receive lysate lots where the certificate states 5.2 mg/mL total protein, and our own BCA assay returns 3.8–4.1 mg/mL. Not every lot. But often enough that we now run in-house verification on every incoming postbiotic shipment rather than accepting the CoA at face value.
All of this is governed under EU Cosmetics Regulation 1223/2009, which doesn’t regulate probiotic ingredient specifications directly but does require the finished product to remain safe and stable throughout its shelf life — a requirement that traces back through every raw material you put into it.
Probiotic and Postbiotic Grade Comparison: Key Specification Parameters #
The table below covers three ingredient categories we use most frequently in our microbiome-probiotic-skincare development projects. These are representative ranges drawn from our qualified supplier list as of Q1 2025, not single-supplier quotes.
| Parameter | Microencapsulated Live Lactobacillus | Spray-Dried Lysate (Bifida/Lactobacillus) | Ferment Filtrate (e.g., Lactobacillus Ferment) |
|---|---|---|---|
| Viable count / Protein | ≥ 10⁹ CFU/g at release; ≥ 10⁷ at 24 months | N/A (non-viable) | 2.5–5.0 mg/mL total protein (BCA) |
| Thermal stability | Stable ≤ 85°C for 10 min (encapsulated) | Stable ≤ 95°C; no viability concern | Stable ≤ 90°C; some enzyme activity loss above 80°C |
| Particle size (D90) | 30–80 µm depending on shell material | 5–20 µm (spray-dried powder) | N/A (liquid filtrate) |
| pH working range | 4.5–6.5 (buffered shell) | 4.0–7.5 | 3.5–7.0 |
| Recommended use level | 0.1–1.0% w/w | 0.5–3.0% w/w | 1.0–5.0% v/v |
| Typical shelf life (sealed, 25°C) | 18–24 months | 24–36 months | 12–18 months |
| Allergen declaration required? | Strain-dependent (dairy-derived strains: yes) | Yes if dairy substrate | Check fermentation substrate |
Grade data based on incoming qualification of 14 commercial lots, Q3 2023–Q1 2025. Individual supplier specifications may vary; always request a current CoA and in-house verification is recommended.
A few things worth calling out from this table. Ferment filtrates have the shortest typical shelf life in the liquid state, which creates packaging compatibility questions — we’ll come back to that. Spray-dried lysates are the most thermally forgiving and the easiest to incorporate, which is probably why they’ve become the default for first-time microbiome product launches. Live microencapsulated grades give you the strongest on-pack story, but the allergen question is one brands consistently underestimate. Dairy-derived Lactobacillus strains — which are common because they’re well-documented — may require allergen labelling in certain EU markets depending on the fermentation substrate, even post-processing. Your regulatory team needs to confirm this before you lock in a strain.
Supplier Qualification — What to Request and What the Response Tells You #
Ask for the complete technical data sheet, not just the CoA. The difference matters. A CoA gives you release specifications. A full TDS includes storage conditions, reconstitution guidance, incompatibility notes, and often the test method used to generate the numbers — which is the part that tells you whether their 10⁹ CFU/g is measured by plate count, qPCR, or flow cytometry. These methods do not produce interchangeable results.
When we evaluate a new postbiotic supplier, the specific request we send includes: total protein by BCA assay (not Bradford), molecular weight distribution by SDS-PAGE (to assess lysate completeness), endotoxin level by LAL test, and a 12-week accelerated stability profile at 40°C/75% RH. If the supplier can turn that around in under 10 business days, they have the testing infrastructure we need. If they come back asking which tests are “really necessary,” that’s a signal.
Endotoxin data is the one most brands skip. For topical cosmetics, endotoxin doesn’t carry the same clinical risk as injectables, but elevated endotoxin in a ferment filtrate can drive skin irritation in sensitive-skin claims — which is exactly the consumer most microbiome brands are targeting. Our internal threshold is ≤ 50 EU/mL for any postbiotic intended for barrier-compromised or sensitive skin formulations. We’re not aware of any published cosmetic-specific standard that sets this limit; it’s a threshold we arrived at through our own sensitization panel data and feedback from our barrier-repair-sensitive development projects.
One more thing: response completeness from a supplier is data. A supplier who sends a well-organized TDS with test methods referenced to ISO Standards and an SDS that correctly categorises the material has invested in quality infrastructure. One who sends a two-page PDF with a single CFU value and no methodology has not. We’ve seen both. You can usually tell within the first exchange.
Ferment Filtrate Stability — One Specification Parameter Examined in Detail #
Ferment filtrates deserve their own section because they’re increasingly popular, the specification language is inconsistent across suppliers, and the stability behaviour is genuinely more complex than most brands expect going in.
A filtrate is not a defined single compound. It’s a mixture of peptides, organic acids, polysaccharides, and metabolites — the exact composition varies with strain, fermentation substrate, culture duration, and post-processing steps. Two lots from the same supplier can have meaningfully different profiles. That’s not a quality failure; it’s the nature of biological production. But it means your stability programme needs to be more rigorous than it would be for a synthetic active.
In our lab, we track ferment filtrate stability across three conditions: 25°C/60% RH (real-time), 40°C/75% RH (accelerated), and freeze-thaw cycling (three cycles, -18°C to 25°C). The parameter we watch most closely is not appearance or pH — it’s antimicrobial peptide (AMP) activity, assessed by inhibition zone against Staphylococcus epidermidis. This is relevant because microbiome briefs often claim “supports healthy skin bacteria balance,” and AMP activity is one mechanism by which a filtrate could actually do that. If it degrades, the claim loses its basis.
Across 11 ferment filtrate lots we’ve evaluated since 2022, AMP activity at 40°C/75% RH dropped below 50% of initial activity by week 10 in four of them. Three of those lots had total protein concentrations below 3.0 mg/mL. The other seven, all above 3.5 mg/mL, held above 50% activity through week 14. That correlation isn’t published anywhere we know of — it’s just a pattern we’ve observed in our own QC data. We’re not prepared to call it a validated predictor yet. Our dataset is 11 lots. We’d need at least 30 to feel confident.
Packaging compatibility with ferment filtrates is an area where projects slow down. At use levels above 3% v/v, several filtrates we’ve tested caused discolouration in low-density polyethylene (LDPE) dropper bottles within 8 weeks at ambient temperature. The discolouration was cosmetic, not a safety or efficacy issue — but it’s still a problem if you’re launching in clear packaging. Glass or PET performed better in our tests. We flag packaging format as a required brief input whenever a brand requests a high-filtrate-load formulation.
The clinical side: a randomised, double-blind, vehicle-controlled study published in the Journal of Cosmetic Dermatology (2022, n=46, 8 weeks, twice-daily application) showed that a 2% Lactobacillus ferment filtrate serum reduced Transepidermal Water Loss (TEWL) by 28% and increased Staphylococcus epidermidis relative abundance by 14% compared to baseline. The vehicle control showed no significant change. This is the reference point we use when brands ask whether filtrate-based products can support a microbiome diversity claim — it’s one of the cleaner studies in this space, with a primary endpoint that’s actually measurable. Whether the TEWL improvement was driven by the filtrate’s AMP activity, its humectant peptide fraction, or the organic acid profile is still not clear. Possibly all three. Nobody can tell you exactly how the mechanism distributes.
The FDA Cosmetics Guidelines don’t currently require microbiome-specific safety testing for topical cosmetics, but they do require that any claim about altering skin microbiome composition be supportable if challenged. That distinction matters in how you write your marketing copy — and it’s a conversation worth having before you lock in claim language.
Formulation Notes for Brand Partners #
When you brief us on a microbiome product, the first thing we need to know is: which market, which format, and what’s the on-pack story? Those three questions aren’t procedural — they drive every specification decision upstream.
Market determines allergen labelling requirements and which postbiotic grades are straightforward to use versus which need additional documentation. Format determines whether you’re in live probiotic territory (requires encapsulation, affects processing temperature, adds cost) or whether a lysate or filtrate serves the brief better with significantly fewer constraints. The on-pack story tells us whether “microbiome-friendly” is a background claim or the hero — because those require different evidence packages.
The brief mistake we see most often: brands request a live probiotic at 10⁹ CFU/g in a water-based serum, no encapsulation, preserved at pH 4.8 with phenoxyethanol-ethylhexylglycerin at 0.9%. That combination will not hold viability past week four. We push back early and redirect toward either full encapsulation (which changes the texture and the cost structure) or a high-protein lysate that gives you a comparable on-pack story without the stability liability.
Timeline: lab samples in 2–3 weeks from brief sign-off, accelerated stability at 40°C/75% RH running over 4–8 weeks, 24-month real-time stability initiated concurrently. For live probiotic grades, add 2 weeks to the lab sample phase for encapsulation optimisation.
Frequently Asked Questions #
Can we put a CFU count on the label if we use an encapsulated probiotic?
A: You can, but the number you claim needs to be the end-of-shelf-life count, not the manufacturing release count. A product released at 10⁹ CFU/g that drops to 10⁶ by month 18 cannot carry a 10⁹ claim on pack — and if your accelerated stability data shows that trajectory, we’ll flag it before you go to print.
Our brief says “EU-compliant microbiome claim” — what does that actually require?
A: The EU Cosmetics Regulation 1223/2009 doesn’t define a specific dossier for microbiome claims, but the SCCS Scientific Opinion framework requires that any functional claim be substantiated by evidence commensurate with the claim’s specificity. A general “microbiome-friendly” claim needs preservation data. A “increases Lactobacillus diversity” claim needs a human study. The gap between those two is significant — in cost, time, and the type of ingredient you need.
We’ve heard ferment filtrates can go brown in the bottle. Is that a real problem?
A: Yes, and it’s usually a packaging issue rather than a formulation failure. Above 3% v/v, several filtrates we’ve tested caused visible discolouration in LDPE dropper bottles within 8 weeks at ambient conditions. Glass and PET both performed better in our observations. If you’re committed to clear plastic packaging, we’d run compatibility screening before you finalise the format.
What’s the MOQ and timeline for a lysate-based serum?
A: Pilot batches run from 20 kg, which is typical for stability and claim substantiation work. Commercial MOQ for a finished microbiome serum is generally 300–500 kg depending on the active grade and packaging complexity. From brief sign-off to first commercial batch, allow 5–6 months if you’re running 24-month real-time stability concurrently, or 4 months if you’re proceeding on accelerated data only.
Should we worry about the fermentation substrate if we’re positioning this as vegan?
A: Yes — and this is something brands often don’t raise until late in the project. Many Lactobacillus strains are cultured on dairy-derived media, which affects both vegan certification and allergen labelling. Ask your supplier specifically about the fermentation substrate, not just the final ingredient. Some suppliers offer plant-substrate fermentation at a cost premium, typically 15–25% above standard grade pricing. If vegan positioning is on-pack, confirm the substrate chain before you qualify the material — not after.
Have a product concept in mind? Contact our formulation team to request a complimentary brief review.
